Difference between revisions of "Idecabtagene vicleucel (Abecma)"
Jump to navigation
Jump to search
| Line 7: | Line 7: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
*3/26/2021: Approved for the treatment of adult patients with relapsed or refractory [[multiple myeloma]] after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. | *3/26/2021: Approved for the treatment of adult patients with relapsed or refractory [[multiple myeloma]] after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. | ||
| + | |||
| + | == Patient Drug Information== | ||
| + | *[https://www.fda.gov/media/147055/download idecabtagene vicleucel (Abecma) Package Insert]<ref>[https://www.fda.gov/media/147055/download idecabtagene vicleucel (Abecma) Package Insert]</ref> | ||
==Also known as== | ==Also known as== | ||
| Line 12: | Line 15: | ||
*'''Generic name:''' ide-cel | *'''Generic name:''' ide-cel | ||
*'''Brand name:''' Abecma | *'''Brand name:''' Abecma | ||
| + | |||
| + | ==References== | ||
[[Category:Chimeric antigen receptor T-cells]] | [[Category:Chimeric antigen receptor T-cells]] | ||
Revision as of 11:17, 4 April 2021
Mechanism of action
Anti-BCMA CAR T-cells.
Diseases for which it is used
History of changes in FDA indication
- 3/26/2021: Approved for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.
Patient Drug Information
Also known as
- Code name: bb2121
- Generic name: ide-cel
- Brand name: Abecma